Get startedLog in
    Picture of ImmuneOnco Biopharmaceuticals (Shanghai) logo

    1541 — ImmuneOnco Biopharmaceuticals (Shanghai) News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    All News

    Brief: Immuneonco Biopharmaceuticals Shanghai Says Approval By NMPA For Phase III Clinical Trial Of IMM01

    Picture of ImmuneOnco Biopharmaceuticals (Shanghai) logoImmuneOnco Biopharmaceuticals (Shanghai)
    03/06/2024 02:33
    June 3 (Reuters) - ImmuneOnco Biopharmaceuticals
Shanghai Inc  1541.HK :
    * APPROVAL BY NMPA FOR PHASE III CLINICAL TRIAL OF IMM01
(TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE
    * APPROVAL BY NMPA FOR FIRST-LINE TREATMENT OF CMML


Further company coverage:  1541.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)

    See all news